Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1880 • ACR Convergence 2020
Association of Healthcare Utilization and Costs with Patient-Reported Outcomes in Patients with Ankylosing Spondylitis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵ and Kaleb Michaud⁶, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: Treatments for ankylosing spondylitis (AS) have been shown to improve patient-reported outcome (PRO) measures in clinical studies; however, healthcare decision makers have limited ability…
Abstract Number: 2014 • ACR Convergence 2020
The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain
Georg Kröber¹, Ulrich Weber², Raj Carmona³, James Yeung⁴, Jon Chan⁵, Sibel Aydin⁶, Liam Martin⁷, Ariel Masetto⁸, Stephanie Keeling⁹, Olga Ziouzina⁷, Sherry Rohekar¹⁰, Rana Dadashova¹¹, Joel Paschke¹¹, Amanda Carapellucci¹¹, Robert G Lambert¹² and Walter Maksymowych⁹, ¹University of Southern Denmark, Sønderborg, Denmark, ²University of South Denmark, Odense, Denmark, ³St. Joseph's Healthcare, Hamilton, ON, Canada, ⁴James Yeung Rheumatology, Vancouver, BC, Canada, ⁵Artus Health Clinic, Vancouver, BC, Canada, ⁶University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Lawson Health Research Institute, London, ON, Canada, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: Patients with psoriasis, iritis, or colitis and back pain represent a high-risk population for the presence of axial spondyloarthritis (axSpA). Clinicians rely on the…
Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
Abstract Number: 1030 • ACR Convergence 2020
Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy
Theresa Hunter¹, Chi Nguyen², Julie Birt³, Joseph Smith², Mingyang Shan³, Hiangkiat Tan², Jeffrey Lisse³ and Keith Isenberg⁴, ¹Eli Lilly and Company, Indianapolis, ²Healthcore, Inc, Wilmington, DE, ³Eli Lilly and Company, Indianapolis, IN, ⁴Anthem, Inc, Indianapolis, IN
Background/Purpose: Pain is a common symptom among ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and can be debilitating, making pain management an integral part…
Abstract Number: 1332 • ACR Convergence 2020
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Milad Baniaamam¹, Sjoerd C. Heslinga², M. Louis Handoko³, Thelma C. Konings³, Otto Kamp³, Vokko P. van Halm⁴, J. Christiaan van Denderen¹, Irene van der Horst-Bruinsma² and Mike Nurmohamed⁵, ¹Reade, Amsterdam, Netherlands, ²Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ⁴Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, ⁵Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR). AVR in AS is caused by…
Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Anna Stein¹, Caleb Anderson² and Angelique Collamer³, ¹Walter Reed National Military Medical Center, Takoma Park, MD, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Walter Reed National Military Medical Center, Silver Spring, MD
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…
Abstract Number: 1881 • ACR Convergence 2020
In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development
Rosalinde Stal¹, Alexandre Sepriano², Floris van Gaalen³, Xenofon Baraliakos⁴, Rosaline van den Berg¹, Monique Reijnierse¹, Juergen Braun⁵, Robert Landewé⁶ and Désirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Portela Loures, Portugal, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁵Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany, ⁶Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), spinal damage manifests as syndesmophytes and facet joint ankylosis (FJA). Whether there is an order in which lesion develops…
Abstract Number: 2020 • ACR Convergence 2020
Preliminary Definition of a Positive MRI for Structural Lesions in the Sacroiliac Joints in Axial Spondyloarthritis
Walter Maksymowych¹, Xenofon Baraliakos², Ulrich Weber³, Pedro M Machado⁴, Susanne J Pedersen⁵, Joachim Sieper⁶, Stephanie Wichuk¹, Denis Poddubnyy⁷, Martin Rudwaleit⁸, Désirée van der Heijde⁹, Robert Landewé¹⁰, Joel Paschke¹¹, Robert G Lambert¹² and Mikkel Østergaard¹³, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ³University of South Denmark, Odense, Denmark, ⁴University College London, London, United Kingdom, ⁵Rigshospitalet University, Copenhagen, Denmark, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ⁹Leiden University Medical Center, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹¹CARE Arthritis, Edmonton, AB, Canada, ¹²University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹³Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: There is lack of international consensus as to what defines a structural lesion on MRI of the sacroiliac joints (SIJ) typical of axial spondyloarthritis…
Abstract Number: 0364 • ACR Convergence 2020
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Helena Marzo-Ortega¹, Corinne Miceli-Richard², Sonja Gill³, Marina Magrey⁴, Paula Machado⁵, Abhijit Shete⁶, Jianyuan Wang⁶, Susanne Rohrer⁶ and Atul Deodhar⁷, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) report pain (70–80%), stiffness (20–40%), and fatigue (50–60%) as the most troubling symptoms. Early diagnosis and sustained improvement…
Abstract Number: 1205 • ACR Convergence 2020
Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy
Anita Pusztai¹, Attila Hamar², Ágnes Horváth², Katalin Gulyás², Edit Végh², Nóra Bodnár², György Kerekes², Monika Czókolyová², Szilvia Szamosi², Levente Bodoki², Katalin Hodosi², Andrea Domján², Gábor Nagy², Luis Lopez³, Ejii Matsuura⁴, Zoltán Prohászka⁵, Sándor Szántó², Zoltán Nagy², Yehuda Shoenfeld⁶, Zoltán Szekanecz² and Gabriella Szűcs², ¹University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ²University of Debrecen, Debrecen, Hungary, ³Corgenix Inc., Broomfield, CO, ⁴Okayama University, Okayama, Japan, ⁵Semmelweis University, Budapest, Hungary, ⁶Zabludowicz Center, Tel-Hashomer, Israel
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular (CV) disease. The treatment of arthritis by tumour necrosis factor α (TNF-α)…
Abstract Number: 1334 • ACR Convergence 2020
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Andrea Delle Sedie¹, Emanuele Calabresi¹, Ilaria Romagnoli¹, Linda Carli² and Marta Mosca², ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…
Abstract Number: 1742 • ACR Convergence 2020
Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis
Laurette van Boheemen¹, Janne Bolt², Marieke ter Wee³, Henriëtte de Jong², Marleen van de Sande⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and immunology Center | Amsterdam UMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁵Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Persons at risk of developing rheumatoid arthritis (RA) may benefit from lifestyle1 or pharmacological2 interventions aimed at primary prevention. Although less studied, the same…
Abstract Number: 1883 • ACR Convergence 2020
Exercise Partially Explains the Impact of Body Mass Index on Disease Activity in Ankylosing Spondylitis
Jean Liew¹, Milena Gianfrancesco², Susan Heckbert¹ and Lianne Gensler³, ¹University of Washington, Seattle, WA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) patients have elevated cardiovascular (CV) morbidity and mortality compared to general population comparators of the same age and sex. Although obesity…
Abstract Number: 2023 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Atul Deodhar¹, Désirée van der Heijde², Joachim Sieper³, Filip Van den Bosch⁴, Walter Maksymowych⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Östör⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Xin Wang¹⁰, Alvina D. Chu¹¹ and In-Ho Song¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁹University of Montpellier, Montpellier, France, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Philip Mease¹, Atul Deodhar², Renato Calheiros³, Xiangyi Meng⁴, Todd Fox⁵ and Xenofon Baraliakos⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Aesch, Switzerland, ⁶Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].